About Us

DalCor is pioneering precision medicine for cardiovascular diseases by tailoring potential new treatments to patients based on their genetic profile.

DalCor is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit.

MORE

Our Science

Approximately 20% of people worldwide have the specific genetic profile.

MORE

dal-GenE Trial

DalCor is conducting dal-GenE (DAL-301), the first interventional precision medicine cardiovascular outcomes trial. This Phase 3 clinical trial will evaluate the efficacy of dalcetrapib versus placebo to reduce clinical cardiovascular events in 6150 patients post-acute coronary syndrome who have a specific genotype.

MORE

Can DalCor Pharma Succeed Where Others Have Failed?

June 1, 2017

DalCor Pharmaceuticals today announced it has exceeded its enrollment schedule with 50 percent of patients randomized in its Phase 3 “dalGenE” clinical trial. More than 2,500 out of 5,000 expected patients with acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene have entered into…

READ MORE ›

Genetically Targeting Dalcetrapib to the Right Patients

April 28, 2017

DalCor Pharmaceuticals seeks to deliver superior clinical cardiovascular outcomes by integrating clinical and genetic insights to target treatments to patients who will derive clinical benefits. The company’s first development program, dalcetrapib, is intended to reduce cardiovascular events in a specific genetic subset of patients.

READ MORE ›

DalCor CVOT Moves Along; Seek Dalcetrapib CETP Win with Roche Diagnostic Test

March 8, 2017

With enrollment about six months ahead of schedule, precision medicine specialist Dalcor Pharmaceuticals Inc. has randomized more than 1,000 patients of the expected 5,000 for the phase III dal-Gene trial, a cardiovascular outcomes (CVOT) study of dalcetrapib in patients with acute coronary syndrome (ACS) who have the AA genotype in…

READ MORE ›

With $150M in the Bank, DalCor Seeks Phase III Success with Dalcetrapib

April 20, 2016

Seeking to succeed where big pharma failed, start-up Dalcor Pharma UK Ltd. completed a $100 million series B round to put an exclamation point on the $50 million series A the company closed late in 2015. The company was launched a year ago by Sanderling Ventures LLC with a new…

READ MORE ›

Startup Aims to Revive Failed Drug

April 20, 2016

A London-based startup is making a risky bet that a surprising genetic variation will enable it to find success in one of the pharmaceutical industry’s biggest flops. DalCor Pharmaceuticals said it has raised $150 million in venture financing to mount a 5,000-patient trial of a cholesterol drug called dalcetrapib that…

READ MORE ›

DalCor Announces Appointment of Paul R. Fonteyne to Chairman of the Board

March 7, 2019

DalCor Pharmaceuticals today announced the appointment of Paul R. Fonteyne to Chairman of the Board effective February 27, 2019.

READ MORE ›

DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease

December 17, 2018

DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease. The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular events in patients with the AA ADCY9 genotype who…

READ MORE ›

DalCor Announces the Appointment of Peter Schuepbach as Vice President of Technical Operations

December 3, 2018

DalCor today announced the appointment of Peter Schuepbach as Vice President of Technical Operations. Mr. Schuepbach will lead product development and supply chain management of dalcetrapib, currently being tested in the dal-GenE Phase 3 clinical trial.

READ MORE ›

DalCor Pharmaceuticals Announces Dr. Fouzia Laghrissi-Thode as Chief Executive Officer

April 9, 2018

DalCor Pharmaceuticals today announced the appointment of Dr. Fouzia Laghrissi-Thode as Chief Executive Officer, effective April 3, 2018. Dr. Laghrissi-Thode is currently on the Board of Directors for DalCor.

READ MORE ›

DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial

April 5, 2018

DalCor today announced that the company will increase enrollment in its ongoing Phase 3 clinical trial of dalcetrapib from 5000 to 6000 patients. The decision for cohort expansion follows better than expected trial enrollment for dal-GenE, which has currently randomized a total of 4300 patients, an estimated 5 months ahead…

READ MORE ›

DalCor Pharmaceuticals Appoints Dr. Fouzia Laghrissi-Thode to the Board of Directors

November 15, 2017

DalCor Pharmaceuticals today announced the appointment of Dr. Fouzia Laghrissi-Thode to its Board of Directors. Dr. Laghrissi-Thode is VicePresident at AstraZeneca. She has been leading the US Renal-Cardiology Therapeutic Area based in San Francisco and previously led the Global Cardiovascular Metabolism Therapeutic Area.

READ MORE ›

DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial — Dalcetrapib Studied in Genetically Targeted Patients with Acute Coronary Syndrome —

August 28, 2017

DalCor Pharmaceuticals today announced it has exceeded its enrollment schedule with 50 percent of patients randomized in its Phase 3 “dalGenE” clinical trial. More than 2,500 out of 5,000 expected patients with acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene have entered into…

READ MORE ›

DalCor Pharmaceuticals to Present at Bloom Burton & Co Healthcare Investor Conference 2017

April 27, 2017

DalCor Pharmaceuticals today announced that senior management will present at the Bloom Burton & Co. Healthcare Investor Conference 2017 on Tuesday, May 2nd at 2:30 pm Eastern Time at the Sheraton Centre Toronto Hotel in Toronto, Canada.

READ MORE ›

DalCor Pharmaceuticals to Present at Needham & Co. Healthcare Conference

March 31, 2017

DalCor Pharmaceuticals today announced that senior management will participate at the 16th Needham & Co. Healthcare Conference taking place April 4-5, 2017 at the Westin Grand Central in New York. Company management will deliver a corporate presentation on Tuesday, April 4, 2017 at 10:20 a.m. ET.

READ MORE ›

DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule — Dalcetrapib Studied in Genetically Distinct Patients with Acute Coronary Syndrome

March 7, 2017

DalCor Pharmaceuticals today announced it is ahead of the enrollment schedule with the randomization of over 1,000 patients of the expected 5,000 patients planned for the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the…

READ MORE ›

DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans

November 10, 2016

DalCor Pharmaceuticals today announced the key investigator in dalcetrapib trials, Jean-Claude Tardif, C.M., M.D., FRCPC, FACC, FAHA, FESC, will present data at the American Heart Association Scientific Sessions 2016 (AHA) during the Abstract Rapid Fire Session on Sunday, November 13, 2016 in New Orleans.

READ MORE ›

DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial

August 23, 2016

DalCor Pharmaceuticals today announced the opening of multiple international clinical trial sites in New Zealand and Europe for its Phase 3 dal-GenE clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. DalCor will also be assembling…

READ MORE ›

DalCor’s Dalcetrapib Demonstrates Genotype-Dependent Effects of Cholesterol Efflux and Inflammation in Data

July 18, 2016

DalCor Pharmaceuticals and The Montreal Heart Institute today announced the publication in Circulation Cardiovascular Genetics of data demonstrating dalcetrapib’s genotype-dependent effects on high-sensitivity C-reactive protein (hs-CRP) from the prospective analysis of a randomized, placebo controlled clinical trial that…

READ MORE ›

DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

April 26, 2016

DalCor Pharmaceuticals today announced it has randomzied the first patient in the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. The worldwide clinical trial will be led by the Montreal Heart Institute.

READ MORE ›

DalCor Pharmaceuticals Completes $150 Million Financing

April 19, 2016

DalCor Pharmaceuticals today announced the completion of $150 million in private financing to continue development of dalcetrapib in a genetically distinct population of patients with cardiovascular disease. DalCor closed a $50 million Series A financing round late in 2015 and a $100 million Series B round this week. Lead investors…

READ MORE ›

Roche to Develop Companion Diagnostic Test for Acute Coronary Syndrome

June 9, 2015

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has entered into an agreement to develop a companion diagnostic (CDx) test for dalcetrapib, a therapeutic from DalCor Pharmaceuticals (DalCor), which will target patients with a specific genotype who have experienced a recent Acute Coronary Syndrome (ACS) event. The CDx test…

READ MORE ›

DalCor Pharmaceuticals Licenses a Late-Stage Investigational Cardiovascular Drug Following Major Discovery by Montreal Heart Institute (MHI) Scientists

June 8, 2015

DalCor Pharmaceuticals Canada Inc. (DalCor) and the Montreal Heart Institute (MHI) announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine. This program is part of a major effort by DalCor and its backers,…

READ MORE ›

Locations

Canada

1010 Sherbrooke St. West, Suite 408
Montreal, Quebec H3A 2R7
Tel.: + 1 514-508-5099
Fax.: + 1 514-564-6424
Email: info@DalCorpharma.com

Switzerland

Baarerstrasse 2
6302 Zug
Tel.: +41 41 727 67 89
Email: info@DalCorpharma.com

United Kingdom

123 Wellington Road South
Stockport, Cheshire, SK1 3TH
Tel: +44 161 507 3221
Email: info@DalCorpharma.com

United States

677 N. Washington Blvd., Suite 32
Sarasota, Florida 34236
Tel: +1 941-306-2362
Email: Info@DalCorpharma.com

Departments

Business Development

Michael Dixon, CPA CA
DalCor Pharmaceuticals
+1 514-508-5099 x 222

Investor Relations

Michael Dixon, CPA CA
DalCor Pharmaceuticals
+1 514-508-5099 x 222

Media Contact

Allison Blum, Ph.D.
LifeSci Public Relations
+1 646-627-8383

The First Interventional Precision Medicine Trial for Cardiovascular Disease

DalCor is conducting dal-GenE (DAL-301), the first interventional precision medicine cardiovascular outcomes trial. This Phase 3  clinical trial is evaluating the efficacy of dalcetrapib versus placebo  to reduce clinical cardiovascular events in 6150 patients post-ACS who carry the ADCY9 rs1967309 AA genotype.

Enrollment for the dal-GenE clinical trial was completed in December 2018 and the results are expected in the first half of 2021.

For more information about the dal-GenE study, please visit clinicaltrials.gov and access NCT02525939.

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib

Black, D.M., Bentley, D., Chapel, S., et al.
Clinical Pharmacokinetics
November 2018

VIEW PUBLICATION ›

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes

Tardif J.C., Rhainds D., Brodeur M., et al.
Circulation: Cardiovascular Genetics
August 2016

VIEW PUBLICATION ›

Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib.Circulation Cardiovascular Genetics

Tardif  J.C., Rheaume E., Lemieux Perreault L-P., et. al.
Circulation: Cardiovascular Genetics
January 2015

VIEW PUBLICATION ›

A Genetic Driven Strategy

With a precision medicine approach, in post-acute coronary syndrome (ACS) DalCor has the opportunity to reduce the risk of cardiovascular events by at least 20% in patients carrying the ADCY9 rs1967309 AA genotype.

Highly consistent, robust preclinical and clinical data, on cardiovascular events, atherosclerosis as well as biomarkers of cholesterol functions and inflammation support the association between the ADCY9 rs1967309 AA genotype and CETP inhibition. These data support the potential clinical benefit of dalcetrapib treatment for CVD patients with the ADCY9 rs1967309 AA genotype.

Atherosclerosis is a major contributor to CVD. The dal-PLAQUE-2 trial, a prospective Phase 3 clinical study which  evaluated the effect of dalcetrapib on atherosclerosis disease progression in patients with evidence of coronary artery disease (CAD). A post-hoc analysis of the trial results found an allele-specific reductions in atherosclerosis in patients with the ADCY9 rs1967309 AA genotype as demonstrated by the reduction of the intima-media thickness (IMT) measured by ultrasonography. This reduction in atherosclerosis was achieved on top of best standard of care and was comparable in magnitude to that reported with statins treatment.

Increased HDL cholesterol efflux has been associated with reduction of cardiovascular events. A post-hoc analysis of the dal-PLAQUE-2 trial results demonstrated allele-specific reduction in cholesterol efflux, with a 22% increase in cholesterol efflux in patients with the ADCY9 rs1967309 AA genotype treated with dalcetrapib.

High sensitivity C-reactive protein (hs-CRP) is a known marker of inflammation and a potential risk factor for CVD. CETP inhibitors have been shown to increase hs-CRP levels in the broad patient populations by 10-15%. A recent publication describes hs-CRP levels measured in 5,243 patients from the dal-OUTCOMES clinical trial. Results demonstrated that patients with the ADCY9 rs1967309 AA genotype did not show significant increase in hs-CRP levels after treatment with dalcetrapib whereas patients with AG and GG genotypes showed increased hs-CRP with dalcetrapib treatment.

Improving Cardiovascular Outcomes with Precision Medicine

Dalcetrapib is a unique cholesterol ester transfer protein (CETP) inhibitor, a class of drugs that has been investigated as therapeutics to reduce the risk of cardiovascular events in more than 100,000 patients in over 100 clinical trials.

Dalcetrapib, while under development by Roche, was evaluated in a Phase 3, double-blind clinical trial, dal-OUTCOMES. The dal-OUTCOMES trial randomized over 15,000 patients with recent acute coronary syndrome (ACS) to investigate the efficacy of dalcetrapib in the prevention of future cardiovascular events.

Dalcetrapib was well tolerated but demonstrated no efficacy in the overall patient population.

In 2012, investigators at the Montreal Heart Institute led by Prof. Jean-Claude Tardif and Marie-Pierre Dubé found a significant association between the effects of dalcetrapib in altering CV events and the allelic polymorphism at the rs1967309 location in the adenylate cyclase type 9 (ADCY9) gene.

Patients with an AA polymorphism had a 39% decline in CV events (dalcetrapib compared to placebo), while GG had a 27% increase, and GA had a neutral effect, in the cohort of dal-Outcomes patients. This retrospective analysis was conducted in 5,749 patients.

Approximately 20% of patients with CVD have the AA genotype and might gain protection from cardiovascular events with the treatment of dalcetrapib.

The Leading Global Cause of Death

Cardiovascular disease (CVD) is the leading cause of death globally, accounting for 25% of deaths in the U.S. and 31% of deaths worldwide. Nearly 18 million people die each year from CVD-related events including heart attack and stroke.

Despite current standard of care treatment, residual risk of heart attack, stroke and death remains high in patients with CVD. Developing new treatments to reduce the residual cardiovascular risk is a challenge due to the heterogeneity of the patient population and the resulting variation in response to treatment.

Scientific advances in precision medicine now allow for a patient’s genetic profile to be considered during the development of new treatments in order to address the complexity of CVD and the heterogeneity of this patient population. This targeted approach identifies individual patients based on a specific genetic subtype, who may benefit from a particular treatment.

DalCor is developing dalcetrapib, a CETP inhibitor, as a precision medicine to reduce cardiovascular risk above and beyond the current standard of care in patients who carry the ADCY9 rs1967309 AA specific genotype.

Paul R. Fonteyne

Chairman

With more than 30 years of global pharmaceutical experience, Paul Fonteyne’s career spans over three decades of leadership roles across North America and Europe with companies including Boehringer-Ingelheim, Merck, and Abbott Laboratories. Until 2018, he was President and CEO, Boehringer-Ingelheim USA. He is past board member of the National Pharmaceutical Council and PhRMA, He serve on the boards of ResTORbio Inc., Gelesis Inc, and Ypsomed AG, Mr. Fonteyne holds an MBA from Carnegie-Mellon University, Pittsburgh, and a degree in Chemical Engineering from the University of Brussels, Belgium.

Domitille de Vienne

Director

Domitille de Vienne has 10 years of experience in investment banking and private equity with a strong focus on healthcare companies. She serves as a director at DalCor and is an Analyst Principal at CDPQ’s global Private Equity group. She is based in London. Before joining CDPQ, she served as an investment professional at Summit Partners in their European healthcare team and has also worked for Citi in investment banking in London. Domitille majored in finance and graduated from the ESCP Europe Business School in Paris, France.

Fouzia Laghrissi-Thode

Director

Fouzia Laghrissi-Thode, was appointed as Chief Executive Officer of DalCor Pharmaceuticals in April 2018. Most recently, Dr. Laghrissi-Thode was Vice-President at AstraZeneca of the US Renal-Cardiology Therapeutic Area. In her previous roles she led the global product and portfolio strategy of the cardiovascular, metabolism and renal therapeutic areas at AstraZeneca and Roche. She has more than 20 years of pharmaceutical industry leadership experience in US and Europe through working in clinical development, global strategic marketing, business development, licensing and M&A. She is a director on the board of Minerva Neurosciences Inc., Nuro Corp. and DalCor Pharmaceuticals. She served as a board member of the Healthcare Businesswomen’s Association (HBA) Europe and was recognized by HBA in 2012 for her work in developing and promoting women leadership in healthcare. From 1992 to 2014, she held an appointment as faculty member at the University of Pittsburgh School of Medicine, UPMC, Western Psychiatric Institute and Clinic. Dr. Laghrissi-Thode is board certified in Psychiatry and holds Doctorate in Medicine from the University of Tours School of Medicine in France.

Henry d’Abo

Director

Henry d’Abo is an experienced bio-tech investor, who has been involved in a number of different Cambridge based start-up companies. Mr. d’Abo serves a director at DalCor and runs his own investment portfolio and has extensive property and agricultural interests in the UK and Germany. Previously, he owned a controlling interest in a US based CRO which was sold in 2000.

 

Jane Guyett

Director

Jane Guyett serves as a director at DalCor and is also Chair of Connect Plus (M25) Ltd, the government’s largest road PFI transaction. Additionally, Jane is the senior non-executive director of UK Government Investments, managing the UK government’s corporate finance and divestment activities, and a non-executive director of UK Financial Investments, managing HM Treasury’s shareholdings in Royal Bank of Scotland, Lloyds Banking Group and UK Asset Resolution. Jane spent 15 years with Bank of America Merrill Lynch where she held various roles in London and New York. She was chief operating officer (EMEA and Asia) of the Global Markets Group and sat on the Board of Bank of America Securities. Following her role at Bank of America Merrill Lynch, Ms. Guyett joined Kerry London Limited and Trade Direct Insurance Services as a non-executive director, positions she has held since 2011. She began her career in Corporate Restructuring at Mitsubishi Bank Ltd London, before joining Bank of America in 1994. Jane Guyett holds a degree in economics.

Laurence Rulleau

Director

Laurence Terrisse Rulleau is currently a Partner at CTI Life Sciences Fund. Previously, Dr. Rulleau served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years. She worked at different firms including Desjardins securities, Yorkton securities and Blackmont securities where she was involved in numerous mergers and acquisitions as well as IPOs.  Dr. Rulleau was ranked the number one Canadian life sciences analyst by the Starmine survey (a Thomson Reuters Company) and number one independent analyst by Brendon Wood survey. Dr. Rulleau was also CEO of HLA-G Technologies a biotechnology start-up based in France and more recently she served as Vice-President Business Development of Univalor, the technology transfer office of Montreal’s university and affiliated schools. Under her responsibility at Univalor in the last 3 years, more than 40 licenses with the industry were signed and 8 companies started. Dr. Rulleau has a master’s degree in biology from The Université du Quebec à Montreal (UQAM) and a doctorate from Montreal University executed at Montreal Clinical Research Institute.

Mark Smith

Director

Mark L. Smith is the President of Pandion Investments Ltd, a private family office that manages the affairs of Bill Sinclair in addition to the investment affairs of André Desmarais. Bill Sinclair is the co-founder of JDS Uniphase, the world’s largest fiber-optic company. André Desmarais is the Vice-Chairman and Co-CEO Power Corporation of Canada, a diversified international and investment and management holding company. Power Corporation of Canada has total assets under administration in its group inexcess of $1 trillion. Mr. Smith attended McGill University’s Business School where he obtained his CA and was a Rhodes Scholar finalist and James McGill scholar. Mr. Smith served as President of Claridge SRB Investments, Senior Vice-President of Investments of the entire Claridge Group and Chief Operating Officer of Claridge Israel. Mr. Smith has a wide range of investment experience in a wide range of industries including the financial services industry, telecommunications, technology, sports, pharmaceuticals, food, media and entertainment, health care and medical services and agro-chemical industries. Mr. Smith’s directorships include and have included Netstar Communications, Medisys Medical Group, Enterprise Capital, Venture Coaches, Interset, Osem Food Group, ECI Telecom Inc., The TNA Group, Campbell Resources, Crowntek Business Systems and CBCI Telecom. In 2013, Mark was awarded the Queen Elizabeth II Diamond Jubilee Medal for his outstanding contributions to Canada.

Robert McNeil

Director

Robert McNeil has over 35 years of experience as an active investor and management participant in seed and early-stage life science companies. He founded Sanderling Ventures in 1979 and has served since then as managing director of Sanderling’s seven investment partnerships. Previously, Dr. McNeil was the seed investor for several companies that became the corner stones in the practice of modern medicine, including Advanced Cardiovascular Systems (the basis of Guidant Corp.) and Ventritex (the basis of rhythm management at St. Jude Medical). His ability to develop a close relationship with management and careful understanding of the companies’ technologies has allowed successful development of products at very early stage. Dr. McNeil earned his doctorate in the fields of molecular biology, biochemistry and genetics from the University of California, Irvine.

Rody Yared

Director

Rody Yared is an accomplished investment banker with over 17 years of experience spanning North America and the Middle East. Rody serves as a director at DalCor and is a managing director of Trussbridge. Prior to Trussbridge, Mr. Yared was responsible for growing J.P. Morgan’s investment banking business in Abu Dhabi from 2010 to 2014. He also managed J.P. Morgan’s equity capital markets business in the MENA region, and was one of the founding members that established the bank’s investment banking franchise in the region in 2007. Previously, Mr. Yared served as head of the Syndicate & Equity Capital Markets department at SHUAA Capital in Dubai, after spending six years at Credit Suisse in New York.

He studied finance at Concordia University.

Royston John Glasspool

Independent Director

Royston John Glasspool is the former Executive Vice President, Head of Corporate Strategy and Customer Operations at Baxalta US, now part of Shire. Mr. Glasspool is currently an advisor to MIT NEWDIGS and leads the FoCUS project looking at pricing and policy with durable oncology Therapies such as CAR-T. As a seasoned pharmaceutical executive with over 25 years of experience in the industry, Mr. Glasspool has extensive experience in multiple line and staff functions in the US, UK, Europe, and global markets through his roles of increasing responsibility at Scotia Pharmaceuticals, Johnson & Johnson, Novartis, Baxter, and Baxalta. This experience has helped him architect innovative approaches to patient-centered drug development within the companies he has served, such as the P5 planning process and patient access approach. Mr. Glasspool has led franchises with over $6B in sales and has launched over 10 products. He is regularly invited to expert panels and also served on the Board of Directors of the Biotechnology Industry Organization (BIO) and was President of Vaccines Europe. Mr. Glasspool is a member of the board of advisors of the non-profit Life Science Cares. Mr. Glasspool holds 2 patents and has degrees in politics and international relations from the University of Staffordshire, UK, and in business administration from Oxford Brookes University with a focus on international marketing.

Serge Langford

Director

Serge Langford is currently Portfolio Manager at Fonds de solidarité FTQ. With 35 years of experience, including 26 years in venture capital, Serge Langford is an expert in the life sciences industry: he is a seasoned professional in managing investment projects and handling large transactions in this field. Prior to his arrival at the Fonds, Mr. Langford worked as a venture capital consultant. He was managing partner at Multiple Capital and before that, Investment Manager at Desjardins Venture Capital. Serge Langford earned a master’s degree in management sciences from HEC Montréal, where he taught a course on managerial economics, offered as part of the management certificate program.

Thomas Birch

Director

Thomas Birch is Managing Director, Venture Capital in the Private Equity team of the Caisse de dépôtet placement du Québec since 2015. In his role, his team contributes to the global expansion and development of innovative Canadian technology companies. Tom Birch has over 30 years of entrepreneurial software operating experience in the contact centre, telecom, CRM and ecommerce markets. Prior to joining CDPQ, he was VP of Corporate Development at Telesystem and Managing Partner of Propulsion Ventures. Tom Birch currently sits on the board of directors of Lightspeed (saas POS), DalCor (personalized medicine), Centech (Centre for Entrepreneurship of ETS – École deTechnologie Supérieure). Some of his former board positions include: Interset (security saas), Woozworld, Adcentricity, Shopit, dna13, eBillme, IVARA and x2oMedia. He has a B.A. Mathematics and a B.Sc. of Computing Science from Queen’s University and a MBA from the Ivey School of Business of University of Western Ontario.

Fouzia Laghrissi-Thode, M.D.

Chief Executive Officer

Fouzia Laghrissi-Thode, was appointed as Chief Executive Officer of DalCor Pharmaceuticals in April 2018. Most recently, Dr. Laghrissi-Thode was Vice-President at AstraZeneca of the US Renal-Cardiology Therapeutic Area. In her previous roles she led the global product and portfolio strategy of the cardiovascular, metabolism and renal therapeutic areas at AstraZeneca and Roche. She has more than 20 years of pharmaceutical industry leadership experience in US and Europe through working in clinical development, global strategic marketing, business development, licensing and M&A. She is a director on the board of Minerva Neurosciences Inc., Nuro Corp. and DalCor Pharmaceuticals. She served as a board member of the Healthcare Businesswomen’s Association (HBA) Europe and was recognized by HBA in 2012 for her work in developing and promoting women leadership in healthcare. From 1992 to 2014, she held an appointment as faculty member at the University of Pittsburgh School of Medicine, UPMC, Western Psychiatric Institute and Clinic. Dr. Laghrissi-Thode is board certified in Psychiatry and holds Doctorate in Medicine from the University of Tours School of Medicine in France.

Donald M. Black, M.D.

Chief Medical Officer

Donald M. Black has over 25 years of experience, during which he has held various senior leadership positions working in clinical development. Dr. Black served as general manager of advanced diabetes care at Becton Dickinson, global leader of research and development as well as general manager of molecular imaging at GE Medical Diagnostics, vice president of global strategic development at Merck and Co, and vice president of clinical research at Parke-Davis, where he was responsible for the clinical development of Lipitor. Dr. Black has served on multiple boards of directors as well as scientific boards, and has over 150 publications, presentations and chapters. His academic appointments include associate professor of pediatric cardiology at the University of Michigan, professor of medicine at the University of Cincinnati, and adjunct professor of medicine, National University of Ireland at Galway. Dr. Black earned his M.D. from University of Michigan Medical School and his MBA University of Cincinnati College of Business.

Michael Dixon, C.P.A., C.A.

Chief Financial Officer

Michael Dixon has over 20 years of experience working in an executive role for venture-backed companies. He was chief financial officer of Gemin X Pharmaceuticals where he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada. Mr. Dixon was Interim COO and vice president of finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening. Mr. Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.

Peter Schuepbach

Vice President, Technical Operations

Peter Schuepbach has more than 30 years of experience in operational management and consulting for major Engineering, Pharma and Biotech companies. He led the development and the implementation of Supply Chain Strategies in several global organizations. Prior to joining DalCor, he was Executive Vice President for Technical Operations at Finox Biotech, an innovative Swiss start-up company. Mr. Schuepbach held the position of Global Supply Chain Leader at Roche Pharma. In this function he was responsible for building the commercial supply chain and launching many of Roche’s major brand product including the launch readiness of the supply chain of dalcetrapib. In 1994 he joined as Head of Supply Chain Planning and Control for the Roche Diagnostics Division. Mr. Schuepbach received his Bachelor of Science in Engineering from the Bern University of Applied Sciences and is an APICS Certified Production and Inventory Manager (CPIM).

Therese Heinonen, D.V.M.

Vice President, Clinical Operations

Therese Heinonen has accumulated over 27 total years of research experience, with 25 years dedicated to clinical research in the areas of cardiology, endocrinology, neurology, and oncology. Dr. Heinonen was a member of the Parke-Davis and Pfizer Global Research and Development cardiovascular senior management teams where she made significant contributions to the clinical development of several products including most notably, Lipitor. Dr. Heinonen has authored over 50 publications and managed over 30 clinical trials, many of which have focused on cardiovascular biomarkers and imaging technologies. Dr. Heinonen has worked as a consultant to government institutions, academic institutions, pharmaceutical companies, biotechnology organizations and diagnostic companies. In 2003, Dr. Heinonen began organizing the annual Cardiovascular Biomarkers and Surrogate Endpoints Symposium and in 2006 co-founded the International Partnership for Critical Markers of Disease. Dr. Heinonen has also founded or significantly contributed to the initiation of several start-up companies. Dr. Heinonen is a graduate of Michigan State University College of Veterinary Medicine and received training in molecular biology at Merck Research Laboratories.

Bruno Pirovino-Zuercher

Director, Swiss Branch

Bruno Pirovino-Zuercher has more than 20 years of managerial experience and consulting for biotech and pharmaceutical companies. Mr. Pirovino-Zürcher is director at the Swiss branch of DalCor and oversees all aspects of the development of dalcetrapib. His international career path encompassed several years in accounting, finance, business and management roles at IMS Health, Pliva International, Eisai Pharmaceuticals and Johnson & Johnson. He holds a bachelor’s degree in business administration and an executive master’s degree in corporate finance from the Lucerne University of Applied Sciences and Arts as well as a CAS in global entrepreneurship from the University of Basel, Switzerland.

Pioneering Precision Medicine for Cardiovascular Disease

DalCor is pioneering precision medicine for cardiovascular disease. The company is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit.

DalCor is currently conducting the dal-GenE study, a Phase 3 precision medicine cardiovascular outcomes trial to determine the efficacy of dalcetrapib in a genetically defined population with cardiovascular disease. The trial has enrolled 6,150 patients post-acute coronary syndrome (ACS) who have the AA genotype at rs1967309 location in the ADCY9 gene. About 20% of the population has this specific genotype. In retrospective analysis of previous trials these patients were identified to have a potentially improved cardiovascular outcome when treated with dalcetrapib.

DalCor has world-wide exclusive rights to develop and commercialize dalcetrapib and CETP inhibitors for the treatment of cardiovascular diseases in patients who have one or more improved response genotypes  through at least  2034. The company has a global presence with offices in Canada, Switzerland, the United Kingdom, and the United States.

Who we are

Our website address is: http://dalcorpharma.insightful.design.

What personal data we collect and why we collect it

Comments

When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s IP address and browser user agent string to help spam detection.

An anonymized string created from your email address (also called a hash) may be provided to the Gravatar service to see if you are using it. The Gravatar service privacy policy is available here: https://automattic.com/privacy/. After approval of your comment, your profile picture is visible to the public in the context of your comment.

Media

If you upload images to the website, you should avoid uploading images with embedded location data (EXIF GPS) included. Visitors to the website can download and extract any location data from images on the website.

Contact forms

Cookies

If you leave a comment on our site you may opt-in to saving your name, email address and website in cookies. These are for your convenience so that you do not have to fill in your details again when you leave another comment. These cookies will last for one year.

If you have an account and you log in to this site, we will set a temporary cookie to determine if your browser accepts cookies. This cookie contains no personal data and is discarded when you close your browser.

When you log in, we will also set up several cookies to save your login information and your screen display choices. Login cookies last for two days, and screen options cookies last for a year. If you select "Remember Me", your login will persist for two weeks. If you log out of your account, the login cookies will be removed.

If you edit or publish an article, an additional cookie will be saved in your browser. This cookie includes no personal data and simply indicates the post ID of the article you just edited. It expires after 1 day.

Embedded content from other websites

Articles on this site may include embedded content (e.g. videos, images, articles, etc.). Embedded content from other websites behaves in the exact same way as if the visitor has visited the other website.

These websites may collect data about you, use cookies, embed additional third-party tracking, and monitor your interaction with that embedded content, including tracking your interaction with the embedded content if you have an account and are logged in to that website.

Analytics

Who we share your data with

How long we retain your data

If you leave a comment, the comment and its metadata are retained indefinitely. This is so we can recognize and approve any follow-up comments automatically instead of holding them in a moderation queue.

For users that register on our website (if any), we also store the personal information they provide in their user profile. All users can see, edit, or delete their personal information at any time (except they cannot change their username). Website administrators can also see and edit that information.

What rights you have over your data

If you have an account on this site, or have left comments, you can request to receive an exported file of the personal data we hold about you, including any data you have provided to us. You can also request that we erase any personal data we hold about you. This does not include any data we are obliged to keep for administrative, legal, or security purposes.

Where we send your data

Visitor comments may be checked through an automated spam detection service.

Your contact information

Additional information

How we protect your data

What data breach procedures we have in place

What third parties we receive data from

What automated decision making and/or profiling we do with user data

Industry regulatory disclosure requirements